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http://dx.doi.org/10.1016/j.jds.2012.0Abstract Background/purpose: Curcumin is a polyphenolic phytochemical isolated from the
medicinal plant Curcuma longa L. This phytochemical exhibits anti-inflammatory and antioxi-
dant properties. The aim of this study was to find a curcuminoid compound that has a better
effect on the suppression of interleukin-1b (IL-1b)-induced IL-6 production than curcumin in
human gingival fibroblasts (HGFs).
Materials and methods: The parent curcuminoids 1e3 were isolated from the rhizomes of
C. longa and 17 curcuminoid analogs 4e20 were synthesized from the parent curcuminoids.
The condition for IL-6 production by HGFs after inducing the cells with IL-1b was optimized.
HGFs were incubated with curcuminoids (0.016e20 mg/mL) for 30 minutes before adding IL-
1b (2 ng/mL). After 24 hours of incubation, the culture media were harvested and determined
for IL-6 contents using an enzyme-linked immunosorbent assay method. Prednisolone, an
immunosuppressive drug, was used as a positive control. Half maximal effective concentration
(EC50) is measured and reported as the concentration required for 50% inhibition of the levels
found in the control medium.
Results: The maximum IL-6 production was achieved when the HGFs were exposed to an IL-1b
concentration of 2 ng/mL for 24 hours; however, addition of the immunosuppressant prednis-
olone inhibited the production of IL-6. Among the analogs, di-O-demethylcurcumin (5) exhib-
ited the most potent anti-IL-6 activity with an EC50 of 2.18  0.07 mg/mL, which was
approximately eightfold more active than the natural curcuminoids 1e3. Cell viability wast of Stomatology, Faculty of Dentistry, Srinakharinwirot University, Sukhumvit 23, Bangkok 10110,
h (N. Aroonrerk).
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Demethylcurcuminoid effects on IL-6 production 351not significantly affected when the concentration of di-O-demethylcurcumin was less than
20 mg/mL.
Conclusion: Di-O-demethylcurcumin exhibited an inhibitory effect on the production of IL-6 by
IL-1b-induced HGFs and can thus serve as a lead compound with its inhibiting property for IL-6
production.
Copyright ª 2012, Association for Dental Sciences of the Republic of China. Published
by Elsevier Taiwan LLC. All rights reserved.Introduction
Chronic inflammation is believed to play a predominant role
in the pathogenesis of periodontal diseases. Persisting
inflammation in the periodontium of patients may be
facilitated by the expression of inflammatory cytokines
including interleukin-1b (IL-1b), a key mediator of various
immunological and inflammatory phenomena,1 which
exhibited a correlation with the severity of periodontal
diseases.2,3 When stimulated with IL-1b, human gingival
fibroblasts (HGFs) were showed increasing bone resorption
and collagenase activity.4 IL-1b was also shown to stimulate
the expression of IL-6 in HGFs.5,6 IL-6 plays an important
role in the pathogenesis of periodontal diseases because it
promotes bone resorption, possibly by stimulating osteo-
clast precursor recruitment and differentiation.7,8 There-
fore, in IL-1b-induced HGFs, IL-6 seems to stimulate
alveolar bone resorption leading to pathogenesis of the
periodontal diseases.
Curcumin (1) is a naturally occurring active antioxidant,9
antitumor,10,11 and anti-inflammatory phytochemical
agent.12 This compound was shown to downregulate the
expression of pro-inflammatory cytokines, such as tumor
necrosis factor-a (TNF-a) and IL-1b isolated from lipopoly-
saccharide (LPS)-stimulated lung cells.13 Results of an
earlier study revealed that long-term oral consumption
of compound 1 in low doses activated peroxisome
proliferator-activated receptor-g, deactivated cell-
mediated immunity, inhibited inducible nitric oxide
synthase, and interfered with adaptive immunity to exac-
erbate the pathogenesis of Leishmania donovani infection
in vivo.14 In addition, the treatment led to the down-
regulation of TNF-a, IL-1b, IL-8, macrophage inflammatory
protein-1a, and macrophage inflammatory protein-1
expression by peripheral blood mononuclear cells.15 The
production of TNF-a16 and inducible nitric oxide synthase
from activated macrophages were also inhibited by
compound 1.17
It has been shown that Jun N-terminal kinase (JNK) is
required for IL-1-induced IL-6 and IL-8 gene expression in
human epithelial carcinoma cell line KB.18 In addition,
curcumin is a potent inhibitor for nuclear factor-kB and
mitogen-activated protein kinase activation.19 Curcumin
has also been shown to inhibit the production of thrombin-
stimulated connective tissue growth factor (CCN2) by
suppressing the activity of JNK in HGFs.20 Because of the
broad anti-inflammatory properties of curcumin, various
studies have started investigating other naturally occur-
ring curcuminoids and their analogs to assess their ability
to inhibit the suppression of IL-1b-induced IL-6production. The results of such studies will provide a basic
knowledge for future studies to develop such compounds
as therapeutic agents for the treatment of periodontal
diseases. This study explains the structural modification
of the parent curcuminoids 1e3 to synthesize analogs
4e20 and evaluates their ability to inhibit the production
of IL-6.Materials and methods
Chemicals and structural modification of
curcuminoid analogs
The parent curcuminoids 1e3 were isolated from the
rhizomes of Curcuma longa and 17 curcuminoid analogs
4e20 (Fig. 1) were synthesized from the curcuminoids 1e3.
This is accomplished as follows: curcumin (1) is demethy-
lated to the corresponding mono-O-demethyl analog 4 and
di-O-demethyl analog 5 (42% and 33% yield, respectively) by
treating it with boron tribromide in dry dichloromethane.
Demethylation of curcuminoid 2 was similarly achieved to
yield the corresponding O-demethyl analog 6 (64% yield).
The spectroscopic [infrared (IR), proton nuclear magnetic
resonance (1H-NMR), and mass spectra] data of 4, 5, and 6
were consistent with the previously reported values.21
Methylation of compounds 1, 2, and 3 was achieved by
treating them with methyl iodide in acetone in the pres-
ence of potassium carbonate to give the corresponding
ether analogs 7e13. The structures of these ether analogs
were characterized by spectroscopic (IR, 1H-NMR, and mass
spectral) data and by spectroscopic spectral comparison
with the previously reported values.22,23 Acetylation of the
parent curcuminoids 1, 2, and 3 using acetic anhydride and
pyridine furnished the acetates 14e20 in good yields. The
structures of these acetates were characterized by spec-
troscopic (IR, 1H-NMR, and mass spectra) data and by
spectroscopic spectral comparison with the reported
values.24,25
Prednisolone (Sigma-Aldrich, St. Louis, MO, USA), an
effective anti-inflammatory agent, was used as a positive
control to inhibit IL-6 production. Stock solutions of the
curcuminoids, prednisolone, and a COX-2 inhibitor, NS-398
(Sigma-Aldrich, St. Louis, MO, USA), were prepared in
dimethyl sulfoxide (DMSO; Sigma-Aldrich, St. Louis, MO,
USA) at a concentration of 10 mg/mL and stored at e20 C
until further use. At the start of each experiment, all
compounds were diluted in Dulbecco’s modified Eagle’s
medium (DMEM; Gibco, Grand Island, NY, USA) with the final
DMSO concentrations not exceeding 0.1%.
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Figure 1 Structures of curcuminoids 1e3 and the curcumi-
noid analogs 4e20.
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HGF cultures were prepared by harvesting healthy gingival
tissues from three volunteers at the time of clinical crown
lengthening and were processed as described previously.26This study was approved by the Faculty of Dentistry
Committee for Ethics, Srinakharinwirot University. Before
treatment, the study objectives were explained to each
patient, and informed consent was obtained. The gingival
tissues were washed two to three times with phosphate-
buffered saline (PBS), cut into small pieces, placed on 35-
mm tissue culture dishes, and covered with a sterilized
glass cover slip. DMEM supplemented with 10% heat-
inactivated fetal bovine serum (Seromed-Biochrom, Ber-
lin, Germany) and 1% antibioticeantimycotic solution
(Gibco, Grand Island, NY, USA) was used as a culture
medium. The cultures were maintained at 37 C in
a humidified incubator (ThermoForma Series II Water
Jacketed CO2 Incubator, Forma Scientific; Marietta, OH,
USA) with 5% CO2 until monolayers of confluent cells were
formed. After trypsinization, the HGFs were allowed to
regrow and routinely expanded using 0.05% trypsin (Gibco,
Grand Island, NY, USA) in PBS containing 0.053 mM ethyl-
enediaminetetraacetic acid in 75-cm2 tissue culture flasks.
These HGFs were used at passages 3e7 in all experiments.
Cytotoxic assay
The effects of the test compounds and control media
(DMEM or DMEMDMSO) on fibroblast viability were deter-
mined by sulforhodamine B (SRB) assay.27 Each well of a 96-
well tissue culture plate (Corning Inc., NY, USA) was seeded
with 1  104 cells in 0.1 mL complete medium and incu-
bated at 37 C for 24 hours. The medium was then removed
and replaced with DMEM or DMEMeDMSO supplemented
with curcuminoids or drugs. After 24 hours, cultured cells
were fixed with trichloroacetic acid for 60 minutes and then
stained for 30 minutes with 0.4% (w/v) SRB sodium salt
(Sigma Chemical Co., St. Louis, MO, USA) dissolved in 1%
acetic acid. The unbound dyes were removed by washing
four times with 1% acetic acid, then the protein-bound dye
was extracted with 10 mM unbuffered Tris base (pH 10.5)
for 5 minutes. Optical density (OD) values were determined
at 490 nm using a microplate reader (Tecan U.S., Durham,
NC, USA). Half maximal inhibitory concentration (IC50)
values were determined by regression analysis and
expressed as mean  standard error of the mean (SEM),
where a minimum of three replicates from two independent
experiments were performed at each of the three
concentrations per test sample.
Optimized condition for IL-6 production by
IL-1b-induced HGFs
To optimize an experimental condition, the condition
necessary for stimulating IL-1b to induce secretion of IL-6
from HGFs was evaluated. HGFs were seeded at 1  105
cells/mL in 96-well plates (100 mL/well) in complete
medium and allowed to adhere overnight at 37 C. The
medium was subsequently removed and each well was
washed once with DMEM. In the time-course experiments,
cells were incubated with DMEM with or without IL-1b
(2 ng/mL; Sigma-Aldrich, St. Louis, MO, USA) for 1e48
hours. In the concentrationeresponse experiments, cells
were incubated for 24 hours with 1e8 ng/mL of IL-1b. The
culture media were harvested at the indicated times and
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Figure 2 Time course (A) and concentration response (B) of
interleukin-1b (IL-1b) on IL-6 production in human gingival
fibroblasts (HGFs). HGFs were incubated with IL-1b (2 ng/mL)
for the indicated times (0e48 hours) or with increasing
concentrations (1e8 ng/mL) of IL-1b for 24 hours. After incu-
bation, the supernatants were evaluated for IL-6 levels by
enzyme-linked immunosorbent assay. Data are representative
of three experiments and expressed as mean  standard error
of the mean. Analysis of variance with HolmeSidak tests
compare IL-6 production relative to the unstimulated control
group (Control), *P < 0.05 (A, B). Paired t tests compare IL-6
production of IL-1b-stimulated and control groups at
a different incubation time, **P < 0.001 (A).
Demethylcurcuminoid effects on IL-6 production 353stored at e80 C before analyzing for IL-6 content using an
enzyme-linked immunosorbent assay (ELISA) method. This
condition was used to evaluate the effects of curcuminoids
and its analogs on the production of IL-6 in the subsequent
experiments.
Inhibition effects of curcuminoids or its analogs on
IL-1b-induced IL-6 production
HGFs (1  105 cells/mL) were seeded in 96-well plates
(100 mL/well) in the culture medium and the cells were
allowed to adhere overnight at 37 C. The medium was
subsequently removed and each well was washed once with
DMEM. Cells were incubated with curcumin (1) or di-O-
demethylcurcumin (5) (0.016e20 mg/mL) for 30 minutes
before adding IL-1b (2 ng/mL). After 24 hours of incubation,
the culture media were harvested and determined for IL-6
contents using an ELISA method. The effects of these
substances on IL-1b-stimulated IL-6 production by HGFs
were calculated in units of ng/mL, and converted to
a percentage of the amount in control medium
(DMEM0.1% DMSO) with IL-1b. Prednisolone, the immu-
nosuppressive drug, was used as a positive control. While
determining the effective concentration of each
compound, half maximal effective concentration (EC50) is
measured and reported as the concentration required for
50% inhibition of the levels found in the control medium.
ELISAs for IL-6 determination
To detect cellular production of IL-6, an ELISA method was
used according to the method suggested by Shirai and co-
workers.28 In brief, a microtiter plate was coated with
100 mL/well of 0.5 ng/mL monoclonal anti-human IL-6
antibody (Sigma-Aldrich, St. Louis, MO, USA) in carbo-
nateebicarbonate buffer (pH 9.6) and incubated overnight
at room temperature. The wells were washed with 0.05%
Tween in PBS (PBS/Tween) and blocked with 1% bovine
serum albumin (BSA) in PBS for 2 hours. Samples and stan-
dards were diluted with 0.1% BSA in PBS and about 100 mL of
sample was added to each well. After washing with PBS/
Tween, 100 mL/well of biotinylated anti-human IL-6 anti-
body (Zymed Laboratories Inc, San Francisco, CA, USA) in
1% BSA was added before incubating the plates for 1 hour.
Each well was washed with PBS/Tween, and 100 mL/well of
streptavidin horseradish peroxidase (Zymed Laboratories
Inc, San Francisco, CA, USA) was added, and the mixture is
further incubated for 1 hour before washing again with
PBS/Tween. A substrate solution of 100 mL/well was added
and incubated for 25 minutes before stopping the reaction
with 1M H2SO4 (100 mL/well). The absorbance was deter-
mined at 450 nm using a microplate reader. In each
experiment, the three wells were repeated and the stan-
dard deviation was calculated.
Statistical analysis
All experiments were set up three times, with each
experiment performed in triplicate, for each cell pop-
ulation of HGFs. Data are presented as means  SEM. Data
were analyzed using SIGMASTAT (SPSS Inc., Chicago, IL,USA). One-way repeated-measurement analysis of vari-
ance, followed by post-hoc testing using the HolmeSidak
method (when appropriate), and Student paired t test were
used for statistical analysis. The level of statistical signifi-
cance was set at P Z 0.05 and 0.001.
Results
Inhibitory effects of curcuminoids and analogs on
IL-1b-induced IL-6 production
Herein, time-dependent and dose-dependent IL-1b stimu-
lation for HGFs have been evaluated. In the time-course
experiments, IL-6 was released into the culture medium as
early as at 1 hour and continued for up to 24 hours. A
significant difference in IL-6 released after stimulating with
IL-1b was observed after 8 hours and after 16e24 hours
(P < 0.001). The amount of IL-6 significantly decreased
after long-term incubation (48 hours) when compared with
24-hour incubation (P Z 0.025) (Fig. 2). Because the
354 N. Aroonrerk et alhighest IL-6 production was obtained after incubating for 24
hours, this duration was used in subsequent experiments. In
the concentrationeresponse experiments, HGFs cultured
with different concentrations of IL-1b (1e8 ng/mL)
produced significantly higher levels of IL-6 as compared
with the control (without IL-1b stimulation; Fig. 2).
Therefore, we decided to use 2 ng/mL of IL-1b and incu-
bated the cells for 24 hours for the condition used to induce
the cytokine production in the subsequent experiments.
The parent curcuminoids 1e3 and the chemically
modified analogs 4e20 were evaluated for the production
of anti-IL-6 from IL-1b-induced HGFs. Compounds 1e3
exhibited anti-IL-6 production, with EC50 values of
16.81  0.09, 16.23  0.22, and 16.02  0.14 mg/mL,
respectively (Table 1). The inhibitory activity of the cur-
cuminoid 1 increased at higher doses. However, with IC50
values of 25.0  1.11 mg/mL, cytotoxic effects on the HGFs
were observed. The monodemethylated analog 4 (Table 1)
showed a slightly higher inhibitory activity (EC50:
14.30  0.25 mg/mL) than that of the parent compound 1.
However, the di-O-demethylated analog 5 was eightfold
more active (EC50 2.18  0.07 mg/mL) than the parent
compound 1. The increase in inhibitory activity was
possibly due to the presence of two sets of 1,2-
dihydroxyphenyl (catechol) moieties. The high activity of
curcuminoid analog with the catechol structure was further
evident from the high activity of the demethylated analog
6, which was about 2.5-fold more active than its parent
compound 2. It was reported that polyhydroxycurcuminoids
displayed excellent antioxidant activity, exhibitedTable 1 Inhibition of IL-6 production and cytotoxic effects of c
Compound
DMEMeDMSO
Curcumin (1)
Demethoxycurcumin (2)
Bisdemethoxycurcumin (3)
Mono-O-demethylcurcumin (4)
Di-O-demethylcurcumin (5)
O-Demethyldemethoxycurcumin (6)
Mono-O-methylcurcumin (7)
Di-O-methylcurcumin (8)
400-O-methyldemethoxycurcumin (9)
40-O-methyldemethoxycurcumin (10)
Di-O-methyldemethoxycurcumin (11)
Mono-O-methylbisdemethylcurcumin (12)
Di-O-methylbisdemethylcurcumin (13)
Mono-O-acetylcurcumin (14)
Di-O-acetylcurcumin (15)
400-O-Acetyldemethoxycurcumin (16)
40-O-Acetyldemethoxycurcumin (17)
Di-O-acetyldemethoxycurcumin (18)
Mono-O-acetylbisdemethylcurcumin (19)
Di-O-acetylbisdemethylcurcumin (20)
DMEM Z Dulbecco’s modified Eagle’s medium; DMSO Z dimeth
HGFs Z human gingival fibroblasts; IC50 Z half maximal inhibitory co
a Values are the mean concentration of substances  standard devia
(2 ng/mL).
b Values are the mean concentration of substances  standard devi
c Inactive at 20 mg/mL.cytotoxicity to lymphocytes, and tumor-reducing activity
on Dalton’s lymphoma ascites tumor cells.29 As expected,
the methyl ether analogs 7 and 8 of the parent compound 1
were less active than the corresponding di-demethylated
analog 5, because the former two analogs lacked the
catechol moiety. In addition, the methyl ether analogs 9,
10, and 11 were less active than their demethylated analog
6 (EC50: 6.64  0.08 mg/mL). Rather surprisingly, the
monomethyl and dimethyl ether analogs 12 and 13 were
approximately 2.5- and 2-folds more active than the parent
compound 3. Furthermore, the monoacetates 14, 16 and
17, and 19 are 2- to 3.5-fold more active than their
respective parent compounds 1, 2, and 3. However, the
diacetates 15, 18, and 20 exhibited low activity. The
relatively higher activity of the methyl ether analogs 12
and 13 and the monoacetate ester analogs 14, 16, 17, and
19 than their respective parent compounds clearly indi-
cated that high inhibitory activity was not just due to the
contribution from free hydroxyl group in the curcuminoid
molecule. It has been reported that some acetate deriva-
tives of curcuminoid exhibited higher antioxidant activity
than the parent compounds.11 However, further study is
needed to provide reasonable explanation for this
observation.Cytotoxic effect of curcuminoids
SRB assay was performed to evaluate the toxicity of cur-
cuminoids and prednisolone. Incubation of HGFs withurcuminoid analogs on HGFs.
EC50 (mg/mL)
a HGFs, IC50 (mg/mL)
b
Inactive Inactivec
16.81  0.09 25.0  1.11
16.23  0.22 24.2  0.57
16.02  0.14 18.0  0.39
14.30  0.25 25.0  0.79
2.18  0.07 Inactivec
6.64  0.08 29.6  0.82
13.61  0.2 Inactivec
8.90  0.32 Inactivec
14.60  0.31 Inactivec
16.04  0.01 Inactivec
16.20  0.32 Inactivec
6.10  0.11 Inactivec
8.01  0.16 Inactivec
7.52  0.08 Inactivec
18.84  0.14 Inactivec
4.47  0.22 14.2  0.19
8.61  0.31 Inactivec
12.41  0.13 Inactivec
5.47  0.22 20.02  0.12
Inactive Inactivec
yl sulfoxide; EC50 Z half maximal effective concentration;
ncentration; IL Z interleukin.
tions that showed 50% inhibition of the control medium with IL-1b
ations that showed 50% inhibition of the control medium.
Demethylcurcuminoid effects on IL-6 production 35520 mg/mL of the test substances for 24 hours altered cell
viability to about 65% of the control. The viabilities of HGFs
after incubating the compounds 1, 2, 3, and 4 for a short
period (24 hours) were shown to be very toxic at the
concentration of 20 mg/mL with viability values of
65.92  0.89%, 61.45  0.56%, 56.42  0.01% and
67.42  0.01%, respectively. Compound 2 was the only
curcuminoid that was toxic at a concentration range of
5e20 mg/mL, whereas all other curcuminoids were nontoxic
at the concentration range of 5e10 mg/mL (Fig. 3). It was
worth noting that increasing the concentration of
compound 5 did not decrease the viability of HGFs. The
result indicated that there was no dose-dependent effect
of compound 5 on the viability of the HGFs. Furthermore,
we found that prednisolone was toxic to HGFs in a dose-
dependent manner. At concentrations of 5e10 mg/mL, the
cell viability of HGFs was reduced by approximately 20e65%
(Fig. 3).Inhibitory effects of prednisolone, compounds 1
and 5 on IL-6 production from IL-1b-induced HGFs
Prednisolone is an anti-inflammatory agent that inhibits
pro-inflammatory cytokine production including IL-6.30 The
effects of this drug on IL-1b-stimulated IL-6 production by
the HGFs were first determined. From our results, the IL-6
production was reduced by approximately 55% upon treat-
ment with 10 mg/mL prednisolone. However, there were no
significant differences in anti-IL-6 production after treat-
ment with the drug at the concentration between 0.16 mg/
mL and 5.0 mg/mL (data not shown). The IL-6 production
was significantly lower in the prednisolone treatment as
compared with the control group (Fig. 4).Cont .16 .31 .63
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Figure 3 Effect of prednisolone, curcumin, and di-O-demethylc
(HGFs). HGFs were incubated with prednisolone, curcumin (1), or di
After incubation, the cell viabilities were measured by sulforhoda
and expressed as mean  standard error of the mean. Analysis o
prednisolone (PDS), curcumin, and DIOD treatment relative to cont
curcumin, and DIOD treatment at a different concentration, **P <Effects of curcumin (1) and di-O-demethylcurcumin (5)
on IL-6 production from IL-1b-induced HGFs were evalu-
ated. Both compounds 1 and 5 inhibited IL-6 production
from IL-1b-induced HGFs. The results indicated that
1.25e20 mg/mL of compound 5 significantly inhibited the
secretion of IL-6 from HGFs in a dose-dependent manner
(Fig. 5). At 20 mg/mL concentration, compound 5 reduced
IL-1b-induced IL-6 production to 40% of the level obtained
with IL-1b-treatment alone (Fig. 5). Compound 5 was more
active in anti-IL-6 properties than the parent compound 1.
As the EC50 value of the compound 5 was eightfold more
active (EC50 2.18  0.07 mg/mL) than the parental
compound 1 (EC50 16.81  0.09 mg/mL) (Table 1), the
inhibitory effect of compound 5 was significantly different
from the control media that is induced with IL-1b alone at
P < 0.05.
Discussion
IL-1b is involved in stimulating the production of protease-
like metalloproteinase and a variety of inflammatory
mediators, and also in inducing bone resorption.1 Of these
mediators, we have chosen IL-6 as indicators of inflamma-
tory process, because they are involved in the development
of inflammation by promoting bone resorption via the
stimulation of osteoclast precursor recruitment and
differentiation.31,32 Consequently, regulating gingival
inflammation may be one way to prevent and control
progression of periodontitis. In this study, we determined
the effects of the natural curcuminoids 1e3 and their
chemically modified analogs 4e20 on IL-6 production to
investigate their potential as inhibitors of inflammatory
process (IL-1b-induced HGFs) by comparing them with an
immunosuppressant drug, prednisolone.1.25 2.5 5 10 20
Prednisolone
Curcumin
DIOD
   *
urcumin (DIOD) on cell viability of human gingival fibroblasts
-O-demethylcurcumin (DIOD, 5) (0.016e20 mg/mL) for 24 hours.
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Figure 4 Effect of substances on interleukin-6 (IL-6)
production from IL-1b-induced human gingival fibroblasts
(HGFs). HGFs were incubated with 10 mg/mL prednisolone
(PDS), 10 mg/mL curcumin, or di-O-demethylcurcumin (DIOD)
for 30 minutes before IL-1b (2 ng/mL) was added. After 24
hours of incubation, the supernatants were evaluated for IL-6
levels by enzyme-linked immunosorbent assay. Data are
representative of three experiments and expressed as
mean  standard error of the mean. Analysis of variance with
HolmeSidak tests compare IL-6 production of PDS, curcumin,
and DIOD treatment relative to IL-1b-stimulated control
(Contþ IL-1b), *P < 0.05, **P < 0.001.
356 N. Aroonrerk et alIn the present study, we have shown that IL-1b induced
IL-6 production by HGFs in a time-dependent manner. At
the concentration of 2 ng/mL, IL-1b could stimulate the
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Figure 5 Effect of curcumin (1) and di-O-demethylcurcumin (5
gingival fibroblasts (HGFs). The HGFs were incubated with curcumin
30 minutes before IL-1b (2 ng/mL) was added. After 24 hours of inc
linked immunosorbent assay. Data are representative of three ex
expressed as mean  standard error of the mean. Analysis of va
curcumin and DIOD treatment relative to IL-1b-stimulated contro
production of curcumin and DIOD treatment at a different concenconcentration of IL-1b can be up to 100 ng/mL for the
stimulation; however, a previous study that used peripheral
blood monocytes showed that it is not necessary to use
a higher amount of IL-1b.33 Therefore, we used this
condition for the experimental model to evaluate the effi-
cacy of the substances to inhibit the inflammatory response
in the tested experiments. In another study, this model has
been used for triclosan to inhibit the production of
inflammation mediators in HGFs.34
IL-1b-stimulated IL-6 production from HGFs was reduced
by treatment with prednisolone as noted earlier. Gluco-
corticoids (dexamethasone, prednisolone, and hydrocorti-
sone) were shown to inhibit IL-6 production from human
lung fibroblasts with a 50% decrease in IL-1-induced IL-6
gene transcription. This effect does fully account for the
potency to induce alterations in IL-6 messenger RNA accu-
mulation and protein production from glucocorticoids.30
The toxic effect of this drug to HGFs was found at
concentrations of 5e10 mg/mL in this study. Prednisolone
has been shown to exhibit a dose-dependent anti-prolifer-
ative effect on human conjunctival fibroblasts.35 Recently,
prednisolone was coupled to human albumin in order to
selectively deliver this steroid drug to macrophages without
causing side effects in some pathological condition.36 Drugs
developed by the pharmaceutical industry have thus far
been associated with toxicity and side effects, which is why
investigating natural substances are of increasing interest.
However, we found that curcumin (1) was not toxic against
HGFs at the concentration less than 10e20 mg/mL after 24
hours of incubation. Our results correlate with the findings
of Chen et al who also did not find toxic effect on HGFs at
the concentration of up to 20 mM (approximately 7.5 mg/
mL).20 In contrast to the present finding, Syng-Ai et al371.25 2.5 5 10 20
Curcumin 
DIOD
( g/ml)
) on interleukin-6 (IL-6) production from IL-1b-induced human
(1) or di-O-demethylcurcumin (DIOD, 5) (0.016e20 mg/mL) for
ubation, the supernatants were evaluated for IL-6 by enzyme-
periments. Data are representative of three experiments and
riance with HolmeSidak tests compare IL-6 production of the
l (Contþ IL-1b) group, *P < 0.05. Paired t tests compare IL-6
tration, **P < 0.001.
Demethylcurcuminoid effects on IL-6 production 357reported that compound 1 had no effect on normal rat
hepatocytes at 50 mM (approximately 15 mg/mL), whereas it
had cytotoxic effects on tumor cell lines by inducing
apoptosis. Compound 1 is not genotoxic in vivo when tested
on Balb-C mice, but in vitro copper and curcumin interac-
tions induce genetic damage.38 The cytotoxic effect of
curcumin on HGFs and its mechanism of action requires
further study.
In HGFs, we found that the anti-IL-6 inhibition of di-O-
demethylcurcumin (5) was more effective compared with
curcumin (1) and the corresponding controls. Compound 5
had been reported to possess an antioxidant activity and
a promising tumor-reducing activity on Dalton’s lymphoma
ascites tumor cells.29 However, an in vitro study of the anti-
inflammatory activity of this compound in HGFs has not
been reported. Compound 1 had some ability to reduce IL-6
especially at high concentrations. This compound has been
shown to inhibit IL-6, IL-8, and TNF-a from LPS-stimulated
macrophages in a dose-dependent manner.15,39 Alter-
ations in IL-6 production in HGFs by compound 5 may thus
be crucial for treating inflammation in patients with
periodontitis.
Compound 5 exhibited an inhibitory effect on the
production of IL-6 by IL-1b-induced HGFs. Although the
activity was not potent compared with conventionally used
drugs, this curcuminoid analog appears to have a potential
as an anti-inflammatory agent for treating chronic inflam-
mation including periodontal disease, either alone or
possibly in combination with other drugs. It may serve as
a lead compound with its inhibiting property for IL-6
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